López-Mínguez José R, Eldoayen-Gragera Javier, González-Fernández Reyes, Fernández-Vegas Concepción, Fuentes-Cañamero María E, Millán-Nuñez Victoria, Nogales-Asensio Juan M, Martínez-Naharro Ana, Sánchez-Giralt Sara, Doblado-Calatrava Manuel, Merchán-Herrera Antonio
Sección de Hemodinámica y Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario Infanta Cristina de Badajoz, Badajoz, Spain.
Sección de Hemodinámica y Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario Infanta Cristina de Badajoz, Badajoz, Spain.
Rev Esp Cardiol (Engl Ed). 2013 Feb;66(2):90-7. doi: 10.1016/j.rec.2012.04.017. Epub 2012 Aug 29.
Left atrial appendage closure can be an attractive option for patients with nonvalvular atrial fibrillation and a contraindication to oral anticoagulants, provided that satisfactory results can be achieved during implantation and follow-up.
Thirty-five consecutive patients, not eligible for randomized trials with oral anticoagulants, had an Amplatzer occlusion device implanted under general anesthesia. After the first 5 patients, 3-dimensional imaging was incorporated. The results of the implantation and the follow-up were analyzed over a 1-year period.
The mean age was 74.65 (7.61) years, with a CHADS2 score of 2.41 (1.53) and a CHA2DS2-VASc score of 3.17 (1.60). Implantation failed in 1 patient and 5 needed a change in the selected plug size. There were no cardiac complications during the implantation or hospital stay. There was 1 vascular complication (arteriovenous fistula). Transesophageal echocardiography monitoring was performed at 24h, 1, 3, 6, and 12 months and we found 5 thrombi which were resolved with heparin. In the follow-up period of 21.14 (10.09) months, 3 patients aged>80 years died, none of them due to heart problems, and one transient ischemic stroke without further consequences.
Left atrial appendage closure by an experienced operator can be a treatment option with few complications and with efficient results at>1 year in reducing thromboembolic and hemorrhagic complications, even in very high-risk groups.
对于非瓣膜性心房颤动且口服抗凝剂存在禁忌的患者,左心耳封堵术可能是一个有吸引力的选择,前提是在植入和随访期间能够取得满意的结果。
35例不符合口服抗凝剂随机试验条件的患者在全身麻醉下植入了Amplatzer封堵器。在前5例患者之后,引入了三维成像技术。对植入和随访1年期间的结果进行了分析。
平均年龄为74.65(7.61)岁,CHADS2评分为2.41(1.53),CHA2DS2-VASc评分为3.17(1.60)。1例患者植入失败,5例需要更换所选封堵器的尺寸。植入过程或住院期间无心脏并发症。有1例血管并发症(动静脉瘘)。在术后24小时、1个月、3个月、6个月和12个月进行经食管超声心动图监测,发现5个血栓,经肝素治疗后消失。在21.14(10.09)个月的随访期内,3例年龄>80岁的患者死亡,均非因心脏问题,1例发生短暂性脑缺血发作,无后续后果。
即使在高危组中,由经验丰富的操作者进行左心耳封堵术也可作为一种并发症少、1年以上减少血栓栓塞和出血并发症效果良好的治疗选择。